Concepedia

Author

Karen McDaid

AstraZeneca (United Kingdom)

Also Known As

K McDaid, K. McDaid, Karen C. McDaid, Karen McDaid

33

Publications

1.1K

Citations

5

H-Index

13

Concepts

All Affiliations

AstraZeneca (United Kingdom)
KM

About

Karen McDaid is an author at AstraZeneca (United Kingdom) specializing in tumor biology, cancer biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

119

2

Cell Biology

2

2

119

3

Immunology

2

2

119

4

Cancer Cell Biology

1

1

33

5

Cell Signaling

1

1

33

Karen McDaid

×

4

Publications

1.1K

Citations

4

H-Index

YearCitations

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Colin W. Steele, Saadia A. Karim, Joshua D.G. Leach,

Cancer Cell

2016

819

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy

Neil R. Smith, Dawn Baker, Matthew R. Farren,

Clinical Cancer Research

2013

134

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo

Catherine A. Eberlein, Jane Kendrew, Karen McDaid,

Oncogene

2012

86

An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

Jane Kendrew, Cath Eberlein, Brad Hedberg,

Molecular Cancer Therapeutics

2011

33

Page 1